MedTrace Logo

Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)

NCT03198468 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-11-15

No results posted yet for this study

Summary

This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment.

Patients will receive BTVA-C treatment followed by standard-of-practice surgical resection.

Conditions

  • Non Small Cell Lung Cancer
  • Metastatic Lung Cancer
  • Lung Cancer

Interventions

DEVICE

Bronchoscopic Thermal Vapor Ablation

Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power (an energy level of 330 calories).

Sponsors & Collaborators

  • Uptake Medical Technology, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel Steinfort, MD, PhD · Melbourne Health, The Royal Melbourne Hospital, City Campus.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-21
Primary Completion
2019-08-20
Completion
2019-08-20

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198468 on ClinicalTrials.gov